Business Context and Reporting Period
Nexalin Technology, Inc. (NXL) filed a Form 8-K on May 14, 2026, reporting the entry into material definitive agreements with GreenLight Ventures LLC (GLV). The filing details the acquisition of PONM, Inc. and a strategic collaboration to support the Company's HALO™ Clarity program and NeuroCare™ virtual clinic.
Key Financial Metrics and Transaction Details
- Transaction Value: The aggregate value of the consideration for the acquisition of PONM is $1.3 million.
- Consideration Structure: Payment is made via the issuance of Nexalin Common Stock (Consideration Shares) in four tranches: 45% at closing, 20% at 90 days, 20% at 180 days, and 15% at 270 days.
- Initial Issuance: On the Closing Date (May 14, 2026), Nexalin issued 959,016 shares of Common Stock to GLV.
- Pricing Mechanism: The number of shares is based on the 30-day volume-weighted average price (VWAP) prior to closing, subject to a floor of $0.61 and a ceiling of $1.15 per share.
- Recurring Costs: Under the Collaboration Agreement, Nexalin will pay GLV $10,000 per month for development services, with additional fees for approved excess services.
Material Changes and Strategic Impact
The primary material change is the acquisition of 100% of PONM, Inc.'s outstanding shares. This transaction secures an exclusive license to GLV's software and platform technology within the "PONM Field of Use." Additionally, the Company entered a 24-month Collaboration Agreement with GLV for development and infrastructure support services. The filing does not provide comparative financial data (revenue, profit, or cash flow) for the current period versus prior periods as this is a current report on specific events rather than a periodic financial statement.
Guidance, Risks, and Contingencies
- Protective Provisions: Unissued Consideration Shares are subject to down-round protection, equitable adjustments for capital changes, and delisting protection.
- Acceleration Clause: Issuance of all remaining unissued shares accelerates upon a change of control of Nexalin.
- Termination Rights: The Collaboration Agreement may be terminated by either party with 180 days' written notice or for uncured material breach. If GLV breaches, Nexalin retains rights to software developed during paid service allotments.
- Intellectual Property: GLV retains ownership of improvements to licensed software but grants Nexalin an exclusive, perpetual, royalty-free license for use within the PONM Field of Use.
Investor Verification Checklist
- Verify the final share count for the remaining tranches based on the 30-day VWAP and the $0.61/$1.15 price caps.
- Review the full text of the Purchase Agreement and Collaboration Agreement (to be filed as exhibits to the Q2 2026 Form 10-Q) for detailed covenants.
- Monitor the impact of the $10,000 monthly service fee and potential excess service costs on future operating expenses.
- Confirm the integration timeline for PONM's technology into the HALO™ Clarity and NeuroCare™ platforms.
- Assess the dilution impact of the initial 959,016 shares and potential future issuances on existing shareholders.